Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is adapting its existing tools, designed for emerging respiratory pathogens, for the current outbreak of global significance. This is an international resource for facilitating the collection of standardised clinical data on patients hospitalised with suspected or confirmed infection with novel coronavirus.

Coronavirus close-up © National Institute of Allergy and Infectious Diseases (NIAID)

On 31st  December 2019, the World Health Organization (WHO) was informed of a cluster of cases of pneumonia of unknown cause in Wuhan City, Hubei Province of the People’s Republic of China. The etiologic agent has been identified as a novel Betacoronavirus (2019-nCoV). Cases of infection with 2019-nCoV have been detected in travellers to Thailand, Japan, Korea and the US, and, on 19th January, the case numbers reported from China increased significantly. The emerging data suggest that person-to-person transmission is occurring, and there is a threat of further escalation and international spread.

In the past, clinical data on emerging infections have not been collected, standardised, or shared quickly enough to inform the outbreak response and patient care. ISARIC – whose Global Support Centre is hosted by the University of Oxford - has a long-standing programme of work on emerging respiratory pathogens which is being adapted for the current outbreak. 

  • Standardised clinical data collection and curation
    Based on a pre-existing ISARIC global observational study of severe acute respiratory infections (SPRINT-SARI), ISARIC has adapted the case record form (CRF) to assist with the collection of standardised clinical data on patients hospitalised with suspected or confirmed infection with nCoV. This CRF will be made available via WHO and other open-access sources as a global resource for public health purposes. A data management platform will be offered by the ISARIC Global Support Centre.
  • Clinical observational studies
    Based on a pre-existing ISARIC Clinical Characterisation Protocol, the federation is making available an observational clinical protocol (with associated patient information leaflets and consent form) that allows data collection that is harmonised with standardised clinical data collection and curation, and sequential biological sampling for research purposes. A data management platform will be offered by the ISARIC Global Support Centre.
  • Clinical trials of therapeutics
    The federation is working with ISARIC partners and with WHO on developing and implementing clinical trials for therapeutics for 2019-nCoV. These are randomised controlled trial protocols.

This work is being supported by a wide range of ISARIC partners and the ISARIC Global Support Centre, as a global resource. Professor Peter Horby, Executive Director of ISARIC, said:

Patients are at the heart of every outbreak. Our work gives local teams the tools they need to react quickly and effectively to this outbreak, doing vital research to advance understanding and improve patient care.

ISARIC stands by the Principles of Data Sharing in public health emergencies as defined through work led by the funders consortium GloPID-R. As such, ISARIC commits to underpinning implementation of timely data sharing. ISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases. ISARIC’s mission is to generate and disseminate clinical research evidence for outbreak-prone infectious diseases, whenever and wherever they occur. ISARIC is funded by the Wellcome Trust, the UK Department for International Development, and the Bill & Melinda Gates Foundation.

Similar stories

Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

The GRAM Project has moved

The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).

Sharing expertise with scientific collaborators in India

The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis

Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.

Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19

The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.

The RECOVERY Trial - two years on

One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.